Standard

Progress toward standardized diagnosis of vascular cognitive impairment : Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. / VICCCS group.

в: Alzheimer's and Dementia, Том 14, № 3, 03.2018, стр. 280-292.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

VICCCS group 2018, 'Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study', Alzheimer's and Dementia, Том. 14, № 3, стр. 280-292. https://doi.org/10.1016/j.jalz.2017.09.007

APA

VICCCS group (2018). Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 14(3), 280-292. https://doi.org/10.1016/j.jalz.2017.09.007

Vancouver

VICCCS group. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia. 2018 Март;14(3):280-292. https://doi.org/10.1016/j.jalz.2017.09.007

Author

VICCCS group. / Progress toward standardized diagnosis of vascular cognitive impairment : Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. в: Alzheimer's and Dementia. 2018 ; Том 14, № 3. стр. 280-292.

BibTeX

@article{8b261010dc5a4f07bef0872d89555719,
title = "Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study",
abstract = "Introduction: Progress in understanding and management of vascular cognitive impairment (VCI) has been hampered by lack of consensus on diagnosis, reflecting the use of multiple different assessment protocols. A large multinational group of clinicians and researchers participated in a two-phase Vascular Impairment of Cognition Classification Consensus Study (VICCCS) to agree on principles (VICCCS-1) and protocols (VICCCS-2) for diagnosis of VCI. We present VICCCS-2. Methods: We used VICCCS-1 principles and published diagnostic guidelines as points of reference for an online Delphi survey aimed at achieving consensus on clinical diagnosis of VCI. Results: Six survey rounds comprising 65–79 participants agreed guidelines for diagnosis of VICCCS-revised mild and major forms of VCI and endorsed the National Institute of Neurological Disorders–Canadian Stroke Network neuropsychological assessment protocols and recommendations for imaging. Discussion: The VICCCS-2 suggests standardized use of the National Institute of Neurological Disorders–Canadian Stroke Network recommendations on neuropsychological and imaging assessment for diagnosis of VCI so as to promote research collaboration.",
keywords = "consensus, Criteria, Delphi, Guidelines, Vascular cognitive impairment, Vascular dementia",
author = "{VICCCS group} and Skrobot, {Olivia A.} and Black, {Sandra E.} and Christopher Chen and Charles DeCarli and Timo Erkinjuntti and Ford, {Gary A.} and Kalaria, {Rajesh N.} and John O'Brien and Leonardo Pantoni and Florence Pasquier and Roman, {Gustavo C.} and Anders Wallin and Perminder Sachdev and Ingmar Skoog and Taragano, {F. E.} and J. Kril and M. Cavalieri and Jellinger, {K. A.} and Kovacs, {G. G.} and S. Engelborghs and C. Lafosse and Bertolucci, {P. H.} and S. Brucki and P. Caramelli and {de Toledo Ferraz Alves}, {T. C.} and C. Bocti and T. Fulop and Hogan, {D. B.} and Hsiung, {G. R.} and A. Kirk and L. Leach and A. Robillard and Sahlas, {D. J.} and Q. Guo and J. Tian and L. Hokkanen and H. Jokinen and S. Benisty and V. Deramecourt and J. Hauw and H. Lenoir and M. Tsatali and M. Tsolaki and U. Sundar and Coen, {R. F.} and Korczyn, {A. D.} and M. Altieri and M. Baldereschi and C. Caltagirone and Kruglov, {L. S.}",
note = "Funding Information: G.A.F. reports personal fees from Pfizer, Athersys, AstraZeneca, Lundbeck, Cerevast, and Daiichi Sankyo, and grants and personal fees from Boehringer Ingelheim, outside the submitted work. J. O'B. reports personal fees from GE Healthcare, TauRx, and Cytox, and grants and personal fees from Avid/Lilly, outside the submitted work. I.S. reports personal fees and other from Takeda, outside the submitted work. Outside the submitted work, S.E.B. reports institutional grants from Pfizer, GE Healthcare, Eli Lilly, Elan/Transition Therapeutics, Roche, and Cognoptix, and personal fees from Pfizer, GE Healthcare, Eli Lilly, Eisai, Boehringer Ingelheim, and Novartis. Funding Information: This work was supported by a project grant (Ref117) from the Alzheimer's Society (UK). Publisher Copyright: {\textcopyright} 2017 the Alzheimer's Association Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2018",
month = mar,
doi = "10.1016/j.jalz.2017.09.007",
language = "English",
volume = "14",
pages = "280--292",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Progress toward standardized diagnosis of vascular cognitive impairment

T2 - Guidelines from the Vascular Impairment of Cognition Classification Consensus Study

AU - VICCCS group

AU - Skrobot, Olivia A.

AU - Black, Sandra E.

AU - Chen, Christopher

AU - DeCarli, Charles

AU - Erkinjuntti, Timo

AU - Ford, Gary A.

AU - Kalaria, Rajesh N.

AU - O'Brien, John

AU - Pantoni, Leonardo

AU - Pasquier, Florence

AU - Roman, Gustavo C.

AU - Wallin, Anders

AU - Sachdev, Perminder

AU - Skoog, Ingmar

AU - Taragano, F. E.

AU - Kril, J.

AU - Cavalieri, M.

AU - Jellinger, K. A.

AU - Kovacs, G. G.

AU - Engelborghs, S.

AU - Lafosse, C.

AU - Bertolucci, P. H.

AU - Brucki, S.

AU - Caramelli, P.

AU - de Toledo Ferraz Alves, T. C.

AU - Bocti, C.

AU - Fulop, T.

AU - Hogan, D. B.

AU - Hsiung, G. R.

AU - Kirk, A.

AU - Leach, L.

AU - Robillard, A.

AU - Sahlas, D. J.

AU - Guo, Q.

AU - Tian, J.

AU - Hokkanen, L.

AU - Jokinen, H.

AU - Benisty, S.

AU - Deramecourt, V.

AU - Hauw, J.

AU - Lenoir, H.

AU - Tsatali, M.

AU - Tsolaki, M.

AU - Sundar, U.

AU - Coen, R. F.

AU - Korczyn, A. D.

AU - Altieri, M.

AU - Baldereschi, M.

AU - Caltagirone, C.

AU - Kruglov, L. S.

N1 - Funding Information: G.A.F. reports personal fees from Pfizer, Athersys, AstraZeneca, Lundbeck, Cerevast, and Daiichi Sankyo, and grants and personal fees from Boehringer Ingelheim, outside the submitted work. J. O'B. reports personal fees from GE Healthcare, TauRx, and Cytox, and grants and personal fees from Avid/Lilly, outside the submitted work. I.S. reports personal fees and other from Takeda, outside the submitted work. Outside the submitted work, S.E.B. reports institutional grants from Pfizer, GE Healthcare, Eli Lilly, Elan/Transition Therapeutics, Roche, and Cognoptix, and personal fees from Pfizer, GE Healthcare, Eli Lilly, Eisai, Boehringer Ingelheim, and Novartis. Funding Information: This work was supported by a project grant (Ref117) from the Alzheimer's Society (UK). Publisher Copyright: © 2017 the Alzheimer's Association Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2018/3

Y1 - 2018/3

N2 - Introduction: Progress in understanding and management of vascular cognitive impairment (VCI) has been hampered by lack of consensus on diagnosis, reflecting the use of multiple different assessment protocols. A large multinational group of clinicians and researchers participated in a two-phase Vascular Impairment of Cognition Classification Consensus Study (VICCCS) to agree on principles (VICCCS-1) and protocols (VICCCS-2) for diagnosis of VCI. We present VICCCS-2. Methods: We used VICCCS-1 principles and published diagnostic guidelines as points of reference for an online Delphi survey aimed at achieving consensus on clinical diagnosis of VCI. Results: Six survey rounds comprising 65–79 participants agreed guidelines for diagnosis of VICCCS-revised mild and major forms of VCI and endorsed the National Institute of Neurological Disorders–Canadian Stroke Network neuropsychological assessment protocols and recommendations for imaging. Discussion: The VICCCS-2 suggests standardized use of the National Institute of Neurological Disorders–Canadian Stroke Network recommendations on neuropsychological and imaging assessment for diagnosis of VCI so as to promote research collaboration.

AB - Introduction: Progress in understanding and management of vascular cognitive impairment (VCI) has been hampered by lack of consensus on diagnosis, reflecting the use of multiple different assessment protocols. A large multinational group of clinicians and researchers participated in a two-phase Vascular Impairment of Cognition Classification Consensus Study (VICCCS) to agree on principles (VICCCS-1) and protocols (VICCCS-2) for diagnosis of VCI. We present VICCCS-2. Methods: We used VICCCS-1 principles and published diagnostic guidelines as points of reference for an online Delphi survey aimed at achieving consensus on clinical diagnosis of VCI. Results: Six survey rounds comprising 65–79 participants agreed guidelines for diagnosis of VICCCS-revised mild and major forms of VCI and endorsed the National Institute of Neurological Disorders–Canadian Stroke Network neuropsychological assessment protocols and recommendations for imaging. Discussion: The VICCCS-2 suggests standardized use of the National Institute of Neurological Disorders–Canadian Stroke Network recommendations on neuropsychological and imaging assessment for diagnosis of VCI so as to promote research collaboration.

KW - consensus

KW - Criteria

KW - Delphi

KW - Guidelines

KW - Vascular cognitive impairment

KW - Vascular dementia

UR - http://www.scopus.com/inward/record.url?scp=85037059982&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2017.09.007

DO - 10.1016/j.jalz.2017.09.007

M3 - Article

C2 - 29055812

AN - SCOPUS:85037059982

VL - 14

SP - 280

EP - 292

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -

ID: 37620580